Charles Gaulin, Preetesh Jain, Ranjit Nair, Swaminathan P Iyer, Hun Ju Lee, Luis Fayad, Lei Feng, Chi Young Ok, Rashmi Kanagal-Shamanna, Onyeka Oriabure, Wendy Chen, Guofan Xu, Anita Deswal, Cezar Iliescu, Maria Badillo, Michelle Ky, Michelle Avellaneda, Guilin Tangc, L Jeffrey Medeiros, Francisco Vega, Christopher R Flowers, Michael L Wang
{"title":"依鲁替尼治疗先前未治疗的高风险阴燃套细胞淋巴瘤的2期试验。","authors":"Charles Gaulin, Preetesh Jain, Ranjit Nair, Swaminathan P Iyer, Hun Ju Lee, Luis Fayad, Lei Feng, Chi Young Ok, Rashmi Kanagal-Shamanna, Onyeka Oriabure, Wendy Chen, Guofan Xu, Anita Deswal, Cezar Iliescu, Maria Badillo, Michelle Ky, Michelle Avellaneda, Guilin Tangc, L Jeffrey Medeiros, Francisco Vega, Christopher R Flowers, Michael L Wang","doi":"10.1080/10428194.2025.2454540","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-5"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.\",\"authors\":\"Charles Gaulin, Preetesh Jain, Ranjit Nair, Swaminathan P Iyer, Hun Ju Lee, Luis Fayad, Lei Feng, Chi Young Ok, Rashmi Kanagal-Shamanna, Onyeka Oriabure, Wendy Chen, Guofan Xu, Anita Deswal, Cezar Iliescu, Maria Badillo, Michelle Ky, Michelle Avellaneda, Guilin Tangc, L Jeffrey Medeiros, Francisco Vega, Christopher R Flowers, Michael L Wang\",\"doi\":\"10.1080/10428194.2025.2454540\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18047,\"journal\":{\"name\":\"Leukemia & Lymphoma\",\"volume\":\" \",\"pages\":\"1-5\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-01-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia & Lymphoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10428194.2025.2454540\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2454540","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor